Who
Morana Jovan-Embiricos
Director
Company insider
Files Form 4 as: Director and 10% owner, Kalaris Therapeutics; Director and 10% owner, Cullinan Therapeutics; Director and 10% owner, Radius Health.
In numbers
- Trades disclosed
- 65
- Buys
- 2
- Sells
- 10
- Bought
- $54.0M
- Sold
- $1.4M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 14 Feb 2014
- Last trade
- 3 Jun 2026
- Last filed
- 4 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 4 Jun 2026 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 10 Apr 2025filed 11 Apr 2025 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 11 May 2023filed 12 May 2023 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 4 Aug 2022filed 4 Aug 2022 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $372K25,989 at $14.31 | filing |
| 3 Aug 2022filed 4 Aug 2022 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $272K19,129 at $14.24 | filing |
| 2 Aug 2022filed 4 Aug 2022 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $68K4,792 at $14.10 | filing |
| 28 Jul 2022filed 1 Aug 2022 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Code A | $3.2M684,622 at $4.61 | filing |
| 28 Jul 2022filed 1 Aug 2022 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Code A | $1.5M325,379 at $4.61 | filing |
| 28 Jul 2022filed 1 Aug 2022 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Code A | $7.5M1,626,898 at $4.61 | filing |
| 28 Jul 2022filed 1 Aug 2022 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Code A | $6.4M1,393,874 at $4.61 | filing |
| 28 Jul 2022filed 1 Aug 2022 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Code A | $4.0M867,678 at $4.61 | filing |
| 28 Jul 2022filed 1 Aug 2022 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Code A | $15.0M3,253,796 at $4.61 | filing |
| 24 Jun 2022filed 28 Jun 2022 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —104,845 at $0.00 | filing |
| 24 Jun 2022filed 28 Jun 2022 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —35,529 at $0.00 | filing |
| 24 Jun 2022filed 28 Jun 2022 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code M | $451K104,845 at $4.30 | filing |
| 24 Jun 2022filed 28 Jun 2022 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code M | $153K35,529 at $4.30 | filing |
| 24 Jun 2022filed 28 Jun 2022 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code F | $604K45,078 at $13.39 | filing |
| 17 May 2022filed 19 May 2022 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.